VolitionRx Limited (NYSE AMERICAN: VNRX) (Volition), a multi-national epigenetics company, announced on Tuesday that it has named Dr Andrew Retter as its new Chief Medical Officer, effective 1 April 2024.

In the new role, Dr Retter is to offer medical leadership at the company and ensure that the firm's scientific and clinical efforts are aligned with patient requirements.

Andrew is serving as an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London. He has worked as a Consultant and heads Clinical Governance in Critical Care, and deals with the management of severe respiratory failure, ECMO and thrombosis in critical care.

Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition. Dr Retter is a leading expert in Intensive Care Medicine and Haematology. As Chief Medical Officer he will be vital to our success - ensuring the needs of the patient are placed at the heart of our research, development and commercialisation activities."